Trial Profile
A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Rilparencel (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors inRegen
- 02 Mar 2024 According to a ProKidney media release, full results from RMCL-002 are expected in 1H 2024
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 13 Nov 2023 Updated positive interim Results published in a ProKidney media release